Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer's Research Tool

<p>Lilly's partnership signals growing industry recognition of AI-driven speech analysis as a path to predicting Alzheimer's disease risk NEW YORK, Oct. 28, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) announces a new collaboration...</p>